Glox Therapeutics Secures £1m PACE Grant for Antibiotic Innovation

Glox Therapeutics, an innovator in the field of precision antibiotic therapies, has been awarded a £1 million grant from PACE—Pathways to Antimicrobial Clinical Efficacy. This initiative is one of the most significant public-private collaborations in the UK focused on early-stage antimicrobial drug and diagnostic discovery. The grant aims to boost Glox Therapeutics' efforts to develop antibiotics derived from naturally occurring bacteriocins, which can effectively tackle antimicrobial-resistant pathogens. The funding highlights the importance of advancing medical research in response to the growing threat of antimicrobial resistance and underscores the role of public-private partnerships in facilitating such advancements.